• British Pharmacopoeia Volume I & II
  • Monographs: Medicinal and Pharmaceutical Substances

Stearic Acid

European Union chaplet of stars
General Notices

(Ph. Eur. monograph 1474)

Action and use

Excipient.

Ph Eur

DEFINITION

Mixture consisting mainly of stearic (octadecanoic) acid (C18H36O2; Mr 284.5) and palmitic (hexadecanoic) acid (C16H32O2; Mr 256.4) obtained from fats or oils of vegetable or animal origin.

Content:

bp2012_v2_13_medicinal_and_pharmaceutical_substances_7 stearicacid_1_2012_70_tb.png


CHARACTERS
Appearance

White or almost white, waxy, flaky crystals, white or almost white hard masses, or white or yellowish-white powder.

Solubility

Practically insoluble in water, soluble in ethanol (96 per cent) and in light petroleum (bp: 50-70 °C).

IDENTIFICATION

A. Freezing point (see Tests).

B. Acid value (2.5.1): 194 to 212, determined on 0.5 g.

C. Examine the chromatograms obtained in the assay.

Results  The principal peaks in the chromatogram obtained with the test solution are similar in retention time to those in the chromatogram obtained with the reference solution.

TESTS
Appearance

Heat the substance to be examined to about 75 °C. The resulting liquid is not more intensely coloured than reference solution Y7 or BY7 (2.2.2, Method I).

Acidity

Melt 5.0 g, shake for 2 min with 10 mL of hot carbon dioxide-free water R, cool slowly and filter. To the filtrate add 0.05 mL of methyl orange solution R. No red colour develops.

Iodine value (2.5.4)

See Table 1474.-1.

Freezing point (2.2.18)

See Table 1474.-1.

bp2012_v2_13_medicinal_and_pharmaceutical_substances_7 stearicacid_2_2012_70_tb.png


Nickel (2.4.31)

Maximum 1 ppm.

ASSAY

Gas chromatography (2.2.28): use the normalisation procedure.

Test solution  In a conical flask fitted with a reflux condenser, dissolve 0.100 g of the substance to be examined in 5 mL of boron trifluoride-methanol solution R. Boil under reflux for 10 min. Add 4.0 mL of heptane R through the condenser and boil again under reflux for 10 min. Allow to cool. Add 20 mL of a saturated solution of sodium chloride R. Shake and allow the layers to separate. Remove about 2 mL of the organic layer and dry it over 0.2 g of anhydrous sodium sulfate R. Dilute 1.0 mL of this solution to 10.0 mL with heptane R.

Reference solution  Prepare the reference solution in the same manner as the test solution using 50 mg of palmitic acid CRS and 50 mg of stearic acid CRS instead of the substance to be examined.

Column:
  • material: fused silica;
  • sizel = 30 m, Ø = 0.32 mm;

Carrier gas  helium for chromatography R.

Flow rate  2.4 mL/min.

Temperature:

bp2012_v2_13_medicinal_and_pharmaceutical_substances_7 stearicacid_3_2012_70_tb.png


Detection  Flame ionisation.

Injection  1 µL.

Relative retention  With reference to methyl stearate: methyl palmitate = about 0.9.

System suitability  Reference solution:

  • resolution: minimum 5.0 between the peaks due to methyl palmitate and methyl stearate;
  • repeatability: maximum relative standard deviation of 3.0 per cent for the areas of the peaks due to methyl palmitate and methyl stearate, after 6 injections; maximum 1.0 per cent for the ratio of the areas of the peaks due to methyl palmitate to the areas of the peaks due to methyl stearate, after 6 injections.
LABELLING

The label states the type of stearic acid (50, 70, 95).

FUNCTIONALITY-RELATED CHARACTERISTICS

This section provides information on characteristics that are recognised as being relevant control parameters for one or more functions of the substance when used as an excipient (see chapter 5.15). This section is a non-mandatory part of the monograph and it is not necessary to verify the characteristics to demonstrate compliance. Control of these characteristics can however contribute to the quality of a medicinal product by improving the consistency of the manufacturing process and the performance of the medicinal product during use. Where control methods are cited, they are recognised as being suitable for the purpose, but other methods can also be used. Wherever results for a particular characteristic are reported, the control method must be indicated.

The following characteristics may be relevant for stearic acid used as a lubricant in tablets and capsules.

Particle-size distribution (2.9.31).
Specific surface area (2.9.26, Method I).

Ph Eur